Jackson Creek Investment Advisors’s Catalyst Pharmaceutical CPRX Stock Holding History

Jackson Creek Investment Advisors’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-77,304	Closed	-$1.91M	–	339
2026 Q1	$1.91M	Buy	77,304 +57,480	+290%	+$1.37M	0.56%	42
2025 Q4	$463K	Buy	+19,824	New	+$442K	0.14%	211
2025 Q3	–	Sell	-19,295	Closed	-$419K	–	291
2025 Q2	$419K	Sell	19,295 -9,989	-34%	-$236K	0.11%	252
2025 Q1	$710K	Sell	29,284 -42,465	-59%	-$956K	0.23%	202
2024 Q4	$1.5M	Sell	71,749 -2,220	-3%	-$47.7K	0.45%	101
2024 Q3	$1.47M	Buy	+73,969	New	+$1.37M	0.44%	123
2024 Q1	–	Sell	-68,203	Closed	-$1.15M	–	313
2023 Q4	$1.15M	Sell	68,203 -7	-0%	-$96	0.44%	56
2023 Q3	$797K	Buy	+68,210	New	+$912K	0.34%	160
2023 Q2	–	Sell	-45,033	Closed	-$747K	–	316
2023 Q1	$747K	Sell	45,033 -24,300	-35%	-$401K	0.31%	177
2022 Q4	$1.29M	Sell	69,333 -2,605	-4%	-$40.1K	0.57%	8
2022 Q3	$923K	Sell	71,938 -55,565	-44%	-$659K	0.43%	65
2022 Q2	$1.31M	Sell	127,503 -10,436	-8%	-$76.5K	0.53%	12
2022 Q1	$1.14M	Buy	+137,939	New	+$975K	0.42%	85

Other funds holding CPRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Jackson Creek Investment Advisors's CPRX Position: Q2 2026 in Review

Jackson Creek Investment Advisors sold out of Catalyst Pharmaceutical (CPRX) in Q2 2026, closing a stake of 77,304 shares — an estimated $1.91M sold.

Jackson Creek Investment Advisors first reported a position in CPRX in Q1 2022 and held it in 13 quarters. The position peaked at $1.91M in Q1 2026. 396 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

Jackson Creek Investment Advisors reported no remaining Catalyst Pharmaceutical position as of Q2 2026 after selling out during the quarter.
Jackson Creek Investment Advisors sold 77,304 Catalyst Pharmaceutical shares in Q2 2026, an estimated $1.91M.
Jackson Creek Investment Advisors first reported a position in Catalyst Pharmaceutical in Q1 2022 and held it in 13 quarters.
Jackson Creek Investment Advisors's Catalyst Pharmaceutical position peaked at $1.91M in Q1 2026.
396 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on Jackson Creek Investment Advisors's 13F filing for Q2 2026, filed 10 Aug 2026.